Racial differences in the treatment and outcomes for prostate cancer in Massachusetts

被引:18
作者
Cole, Alexander P. [1 ,2 ]
Herzog, Peter [1 ,2 ]
Iyer, Hari S. [3 ,4 ]
Marchese, Maya [1 ,2 ]
Mahal, Brandon A. [5 ]
Lipsitz, Stuart R. [2 ,6 ]
Nyambose, Joshua [7 ]
Gershman, Susan T. [7 ]
Kennedy, Mark [8 ]
Merriam, Gail [7 ]
Rebbeck, Timothy R. [3 ,4 ]
Trinh, Quoc-Dien [1 ,2 ]
机构
[1] Harvard Med Sch, Brigham & Womens Hosp, Div Urol Surg, 45 Francis St,ASB II-3, Boston, MA 02115 USA
[2] Harvard Med Sch, Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Div Populat Sci, Boston, MA 02115 USA
[4] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA
[5] Harvard Med Sch, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA
[6] Harvard Med Sch, Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA
[7] Massachusetts Dept Publ Hlth, Boston, MA USA
[8] Boston Publ Hlth Commiss, Boston, MA USA
基金
美国国家卫生研究院;
关键词
prostate cancer; racial disparities; surgical outcomes; RADICAL PROSTATECTOMY; AFRICAN-AMERICAN; UNITED-STATES; DISPARITIES; RISK; RACE; CARE; MORTALITY; SURVIVAL; MEN;
D O I
10.1002/cncr.33564
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Massachusetts is a northeastern state with universally mandated health insurance since 2006. Although Black men have generally worse prostate cancer outcomes, emerging data suggest that they may experience equivalent outcomes within a fully insured system. In this setting, the authors analyzed treatments and outcomes of non-Hispanic White and Black men in Massachusetts. Methods White and Black men who were 20 years old or older and had been diagnosed with localized intermediate- or high-risk nonmetastatic prostate cancer in 2004-2015 were identified in the Massachusetts Cancer Registry. Adjusted logistic regression models were used to assess predictors of definitive therapy. Adjusted and unadjusted survival models compared cancer-specific mortality. Interaction terms were then used to assess whether the effect of race varied between counties. Results A total of 20,856 men were identified. Of these, 19,287 (92.5%) were White. There were significant county-level differences in the odds of receiving definitive therapy and survival. Survival was worse for those with high-risk cancer (adjusted hazard ratio [HR], 1.50; 95% CI, 1.4-1.60) and those with public insurance (adjusted HR for Medicaid, 1.69; 95% CI, 1.38-2.07; adjusted HR for Medicare, 1.2; 95% CI, 1.14-1.35). Black men were less likely to receive definitive therapy (adjusted odds ratio, 0.78; 95% CI, 0.74-0.83) but had a 17% lower cancer-specific mortality (adjusted HR, 0.83; 95% CI, 0.7-0.99). Conclusions Despite lower odds of definitive treatment, Black men experience decreased cancer-specific mortality in comparison with White men in Massachusetts. These data support the growing body of research showing that Black men may achieve outcomes equivalent to or even better than those of White men within the context of a well-insured population. Lay Summary There is a growing body of evidence showing that the excess risk of death among Black men with prostate cancer may be caused by disparities in access to care, with few or no disparities seen in universally insured health systems such as the Veterans Affairs and US Military Health System. Therefore, the authors sought to assess racial disparities in prostate cancer in Massachusetts, which was the earliest US state to mandate universal insurance coverage (in 2006). Despite lower odds of definitive treatment, Black men with prostate cancer experience reduced cancer-specific mortality in comparison with White men in Massachusetts. These data support the growing body of research showing that Black men may achieve outcomes equivalent to or even better than those of White men within the context of a well-insured population.
引用
收藏
页码:2714 / 2723
页数:10
相关论文
共 50 条
  • [21] Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER-Medicare investigation
    Beebe-Dimmer, Jennifer L.
    Ruterbusch, Julie J.
    Cooney, Kathleen A.
    Bolton, Adam
    Schwartz, Kendra
    Schwartz, Ann G.
    Heath, Elisabeth
    CANCER MEDICINE, 2019, 8 (06): : 3325 - 3335
  • [22] Benign prostatic hyperplasia: racial differences in treatment patterns and prostate cancer prevalence
    Pettaway, Curtis A.
    Lamerato, Lois E.
    Eaddy, Michael T.
    Edwards, Jessie K.
    Hogue, Susan L.
    Crane, Martin M.
    BJU INTERNATIONAL, 2011, 108 (08) : 1302 - 1308
  • [23] Racial/ethnic differences in the outcomes of patients with metastatic breast cancer: contributions of demographic, socioeconomic, tumor and metastatic characteristics
    Ren, Jin-Xiao
    Gong, Yue
    Ling, Hong
    Hu, Xin
    Shao, Zhi-Ming
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 173 (01) : 225 - 237
  • [24] Obesity, race, and long-term prostate cancer outcomes
    Vidal, Adriana C.
    Oyekunle, Taofik
    Howard, Lauren E.
    De Hoedt, Amanda M.
    Kane, Christopher J.
    Terris, Martha K.
    Cooperberg, Matthew R.
    Amling, Christopher L.
    Klaassen, Zachary
    Freedland, Stephen J.
    Aronson, William J.
    CANCER, 2020, 126 (16) : 3733 - 3741
  • [25] Racial/Ethnic Differences in Treatment Discussed, Preferred, and Received for Prostate Cancer in a Tri-Ethnic Population
    Hosain, G. M. Monawar
    Sanderson, Maureen
    Du, Xianglin L.
    Chan, Wenyaw
    Strom, Sara S.
    AMERICAN JOURNAL OF MENS HEALTH, 2012, 6 (03) : 249 - 257
  • [26] Racial Differences in Prostate Cancer Characteristics and Cancer-Specific Mortality: An Overview
    Hinata, Nobuyuki
    Fujisawa, Masato
    WORLD JOURNAL OF MENS HEALTH, 2022, 40 (02) : 217 - 227
  • [27] Isolating the Drivers of Racial Inequities in Prostate Cancer Treatment
    Hammarlund, Noah
    Holt, Sarah K.
    Basu, Anirban
    Etzioni, Ruth
    Morehead, Dante
    Lee, Jenney R.
    Wolff, Erika M.
    Gore, John L.
    Nyame, Yaw A.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2024, 33 (03) : 435 - 441
  • [28] Hospital racial composition and the treatment of localized prostate cancer
    Pollack, Craig Evan
    Bekelman, Justin E.
    Liao, K. J.
    Armstrong, Katrina
    CANCER, 2011, 117 (24) : 5569 - 5578
  • [29] Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis
    Derman, Benjamin A.
    Jasielec, Jagoda
    Langerman, Spencer S.
    Zhang, Wei
    Jakubowiak, Andrzej J.
    Chiu, Brian C-H
    BLOOD CANCER JOURNAL, 2020, 10 (08)
  • [30] Racial Differences in the Diagnosis and Treatment of Prostate Cancer
    Di Pietro, Giuliano
    Chornokur, Ganna
    Kumar, Nagi B.
    Davis, Chemar
    Park, Jong Y.
    INTERNATIONAL NEUROUROLOGY JOURNAL, 2016, 20 : 112 - 119